2025 · Journal of clinical microbiology · open access
Sensitivity and specificity of the Cobas Liat CT/NG/MG nucleic acid test in a clinical laboratory setting and point-of-care location
Van Der Pol et al.
The finding, in our words
The Cobas Liat CT/NG/MG nucleic acid amplification test achieved 97% specificity for chlamydia, gonorrhoea, and mycoplasma from self-collected urine and vaginal swabs at point-of-care, with sensitivity of at least 92% for most specimen types. Sensitivity was modestly lower for female urine (77–87%), yet the 20-minute turnaround time and ease of use support rapid, decentralised STI screening and reduced empiric treatment.
A paraphrase to the Library’s standard, never the abstract. The source is one link away and is always the authority.
Midstream urine self-collection demonstrated adequate sensitivity for Chlamydia trachomatis screening in asymptomatic patients, although it was less sensitive than vaginal swabs in women, and the study confirmed that nucleic acids in neat urine remain stable for up to seven days when stored at 4°C.
Ilardo et al., The new microbiologica (paywalled) · source ↗
This study found strong agreement between self-collected urine samples tested with the INDICAID HPV assay and clinician-collected swabs tested with the BD Onclarity assay for detecting high-risk HPV. The results suggest that urine-based self-collection offers a reliable alternative for cervical cancer screening, potentially improving access for women who face barriers to standard care.
Yung et al., Journal of gynecologic oncology (paywalled) · source ↗
Self-collected urine samples matched clinician-collected cervical samples in detecting all seven CIN3 lesions among hrHPV-positive women when extended HPV typing was used, showing 82% concordance for hrHPV detection. This indicates urine self-collection could serve as a patient-centric, decentralised screening option for cervical precancer without compromising diagnostic yield.
Meneses-León et al., Cancer causes & control : CCC · source ↗
Urine self-sampling for HPV detection showed good agreement with clinician-collected cervical samples (Kappa 0.72) under optimised conditions of 40 mM EDTA preservative, storage at 25°C, and processing within 72 hours. With a cost of USD 1.10 and high acceptability among women and healthcare workers, this method offers a practical decentralised screening approach for resource-limited settings.
In women with HPV, first-void urine collected with the Colli-Pee device had higher HPV DNA concentrations than urine collected with a standard cup, although this advantage disappeared at high HPV DNA loads. Timing of collection (morning versus later) did not affect HPV DNA copies.
Pattyn et al., Journal of virological methods (paywalled) · source ↗